ClinVar Miner

Submissions for variant NM_000244.3(MEN1):c.355_357AAG[1] (p.Lys120del) (rs794728657)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000182460 SCV000234805 pathogenic not provided 2018-04-25 criteria provided, single submitter clinical testing The c.358_360delAAG variant in the MEN1 gene has been reported in many individuals clinically diagnosed with multiple endocrine neoplasia type 1 (MEN1) (for examples, see Agarwal et al., 1997; Mayr et al., 1998l Dackiw et al., 1999; Goroshi et al., 2016). Functional analyses demonstrate that this variant results in an unstable menin protein subject to rapid degradation and resulting in an 80% reduction in protein expression relative to wild-type (Shimazu et al., 2011). The c.358_360delAAG variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The c.358_360delAAG variant is an in-frame deletion that results in the loss of a single Lysine residue, denoted p.Lys120del. The residue removed by this deletion is conserved across species. Based on currently available evidence, we consider c.358_360delAAG to be pathogenic.
Invitae RCV000018160 SCV000541188 pathogenic Multiple endocrine neoplasia, type 1 2019-01-07 criteria provided, single submitter clinical testing This sequence change deletes 3 nucleotides from exon 2 of the MEN1 mRNA (c.358_360delAAG). This leads to the deletion of 1 amino acid residue in the MEN1 protein (p.Lys120del) but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (rs794728657, ExAC no frequency). This variant has been reported to segregate with hyperparathyroidism in a single family (PMID: 12807514). It has also been reported as one of the most common variants in individuals with multiple endocrine neoplasia type 1 (PMID: 9103196, 22470073, 17879353). This variant is also known as K119del in the literature. ClinVar contains an entry for this variant (Variation ID: 201019). Experimental studies have shown that this in-frame deletion destabilizes the MEN1 protein, likely as a result of protein misfolding, and leads to its degradation by the proteasome (PMID: 21819486, 15254225). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV000491280 SCV000579630 pathogenic Hereditary cancer-predisposing syndrome 2015-04-01 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Deficient protein function in appropriate functional assay(s),Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation,Other strong data supporting pathogenic classification,In silico models in agreement (deleterious) and/or completely conserved position in appropriate species,Rarity in general population databases (dbsnp, esp, 1000 genomes),Other data supporting pathogenic classification
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000018160 SCV001158533 pathogenic Multiple endocrine neoplasia, type 1 2019-06-04 criteria provided, single submitter clinical testing The MEN1 c.358_360delAAG; p.Lys120del variant (rs794728657), also known as K119del, is reported in the literature in multiple individuals and families affected with multiple endocrine neoplasia type 1 (Chandrasekharappa 1997, Klein 2005, Lemos 2008, Tso 2003). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 201019), and is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This variant deletes a single lysine residue leaving the rest of the protein in-frame, but functional analyses of the variant protein show destabilization of the MEN1 protein leading to degradation by the proteasome (Shimazu 2011, Yaguchi 2004). Based on available information, this variant is considered to be pathogenic. References: Chandrasekharappa SC et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997 276(5311):404-7. Klein RD et al. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med. 2005 7(2):131-8. Lemos MC and Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008 Jan;29(1):22-32. Shimazu S et al. Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. Cancer Sci. 2011 102(11):2097-102. Tso AW et al. Multiple endocrine neoplasia type 1 (MEN1): genetic and clinical analysis in the Southern Chinese. Clin Endocrinol (Oxf). 2003 Jul;59(1):129-35. Yaguchi H et al. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol. 2004 Aug;24(15):6569-80.
OMIM RCV000018160 SCV000038439 pathogenic Multiple endocrine neoplasia, type 1 1997-04-18 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.